Brief: Gyre Therapeutics announces last patient completed pivotal phase 3 trial evaluating F351 For CHB-associated liver fibrosis
22/10/2024 22:17
Oct 22 (Reuters) - Gyre Therapeutics Inc GYRE.O :
* GYRE THERAPEUTICS ANNOUNCES LAST PATIENT COMPLETED PIVOTAL
PHASE
3 TRIAL EVALUATING F351 FOR CHB-ASSOCIATED LIVER FIBROSIS
* GYRE THERAPEUTICS INC - EXPECTS TOPLINE DATA FROM PHASE 3
TRIAL
BY Q1 2025
Source text for Eikon: ID:nGNX2hlbk0
Further company coverage: GYRE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Gyre Therapeutics
See all newsBrief: Gyre Therapeutics - Enters Employment Agreement With Ying Luo As CEO - SEC Filing
Gyre Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Gyre Therapeutics, Inc. expected to post a loss of 13 cents a share - Earnings Preview
Brief: Gyre Therapeutics Reports Second Quarter 2026
Gyre Therapeutics Q2 revenue beats estimates on higher ETUARY sales volumes